Skip Navigation
Toggle Navigation
Search:
Search Submit
About
Our Company
Executive Team
Partners
Our Culture
Programs
Pipeline
Scientific Presentations
Clinical Trials
Expanded Access Policy
News
News & Press Releases
Careers
Who We Are
Job Opportunities
Contact Us
Programs
Scientific Presentations
09.10.2023
FAVOUR: A phase 1b study of furmonertinib, an oral, brain penetrant, selective EGFR inhibitor, in patients with advanced NSCLC with EGFR Exon 20 insertions
09.09.2022
Furmonertinib is an Oral, Irreversible, Highly Brain-Penetrant Pan-EGFR Mutant Inhibitor with Activity Against Classical and Atypical EGFR Mutations
03.08.2022
FURLONG: Furmonertinib versus gefitinib in treatment-naïve EGFR mutated non-small cell lung cancer: a randomized, double-blind, multi-center, phase III study
09.16.2021
Preclinical and Preliminary Clinical Investigations of Furmonertinib in NSCLC with EGFR exon 20 insertions (20ins)
